Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
121182032 | 12118203 | 2 | F | 20160813 | 20160226 | 20160822 | EXP | US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-011885 | BRISTOL MYERS SQUIBB | 0.00 | F | Y | 0.00000 | 20160822 | PH | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
121182032 | 12118203 | 1 | PS | SPRYCEL | DASATINIB | 1 | Oral | 40 MG, 6 DAYS/WK | U | 21986 | 40 | MG | FILM-COATED TABLET | ||||||
121182032 | 12118203 | 2 | SS | SPRYCEL | DASATINIB | 1 | Oral | 20 MG, 1 DAY/WEEK | U | 21986 | 20 | MG | FILM-COATED TABLET |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
121182032 | 12118203 | 1 | Neoplasm malignant |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
121182032 | 12118203 | HO |
121182032 | 12118203 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
121182032 | 12118203 | Agranulocytosis | |
121182032 | 12118203 | Off label use |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
121182032 | 12118203 | 1 | 20150911 | 0 |